Renal Medicine, York Teaching Hospital NHS Foundation Trust, York, United Kingdom INTRODUCTION AND AIMS: Hemodialysis (HD) patients experience significant symptom burden and effects on health-related quality of life. Physical and mental symptoms are a barrier to complex behaviour change such as self care. Previous studies have shown increases in end points such as volume status, hyperkalaemia, hospitalisation and mortality immediately after two day break in 3 times a week in-centre HD, however the relationship between HD day and symptom burden has not been formally quantified.
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METHODS:
Patients participating in quality improvement programme to teach patients to undertake dialysis related tasks (SHAREHD) completed the Think Kidneys Your Health Survey(YHS) (including POS-S Renal and EQ5D-5L) at baseline, 6 and 12 months. All YHS completed by three times a week in-centre dialysis patients were identified. Logistic regression (LR) was used to predict the presence of each of 17 symptoms (mild to overwhelming compared to none) adjusting for age, sex and time on HD. HD day of the week was treated as continuous variable which increased with each HD session from two day break (i.e. 1,2,3), and separately HD compared non-HD days categorically. Elements of the EQ5D were also evaluated. RESULTS: From a cohort of 586 patients participating in SHAREHD, 1157 YHS completed by 445 patients that could be assigned a HD day (370 on Mon/Tue, 403 on Wed/ Thu, 191 on Fri/Sat, 193 on non-HD days) were analysed. Across the week, the prevalence of symptoms were high: pain (64.8%), nausea (36.9%), poor mobility (69.2%), breathlessness (56.0%), poor appetite (48.0%), drowsiness (66.5%), anxiety (48.0%) and depression (46.7%). EQ5D quality of life (QOL) was 0.70 (95% CI 0.68-0.71) , comparable to other HD cohorts. Pain and nausea significantly improved with increasing time from the 2 day break. Prevalence of pain was 66.9%, 64.5% and 55.3% for the 1st, 2nd and 3rd HD day respectively (LR: 23% improvement per HD day, 95% CI 7.6-36.6%, p¼0.005). Prevalence of nausea was 39.9%, 36.7% and 30.3% respectively (20% per HD day, 95%CI 3.2-33.6%, LR p¼0.022). No statistically significant relationship was identified for the remaining symptoms and EQ5D QOL was similar across the HD days (0.71, 0.69, 0.73, P¼0.284). Patients who responded on non-HD days had higher symptom burden: pain (70.8% vs 63.6%, LR p¼0.022), breathlessness (64.3% vs 54.4%, LR p¼0.010), mobility (79.0% vs 69.2%, LR p¼0.004), sleeping (72.2% vs 63.5%, LR p¼0.02). Weakness, anxiety and constipation were borderline (LR p<0.15) and EQ5D was non-significantly reduced (0.66 vs 0.70, p¼0.64). CONCLUSIONS: Symptom burden is high in in-centre HD patients, suggesting that measurement of these as clinical outcomes is relevant. Patients who responded on non-HD days, possibly at home, reported greater burden of some symptoms and non-significantly lower EQ5D QOL suggesting issues surrounding environment and symptom perception. Pain and nausea lessen as time from 2 day break increases. Researchers should ensure evaluation of symptoms and QOL are conducted in a standardised location and specific HD days to minimise the risk of bias. Nephrology, Yabuki Hospital, Yamagata, Japan
INTRODUCTION AND AIMS:
The Japanese Society for Dialysis Therapy (JSDT) guidelines recommend the use of high-performance membrane (HPM) dialyzers, including high-flux membrane dialyzers because they have the potential to improve patients' prognosis and reduce dialysis-related complications, and are thus considered for use in dialysis therapy. There are seven types of HPM dialyzers in Japan: cellulose triacetate (CTA), ethylene vinyl alcohol (EVAL), polyacrylonitrile (PAN), polyester polymer alloy (PEPA), polyethersulfone (PES), polymethylmethacrylate (PMMA), and polysulfone (PS). However, there is little information available regarding which type of dialyzer results in good prognosis. Therefore, we conducted a cohort study from a nationwide registry of hemodialysis (HD) patients in Japan to clarify the association between different dialyzers and 2-year mortality rate. METHODS: We conducted a cohort study using data from a nationwide registry of the JSDT. Subjects were 136,676 patients on maintenance HD between 2009 and 2011who underwent maintenance HD for at least 2 years and were treated with one of the following seven types of HPM dialyzers: CTA, EVAL, PAN, PEPA, PES, PMMA, and PS. Survival analyses with Cox proportional hazards regression were used to examine whether baseline basic factors including age, sex, dialysis duration, and primary kidney disease and cardiovascular comorbidity predicted survival for up to 2 years of follow-up. Additional analyses were performed adjusted for dialysis dose and b 2 -microglobulin. Furthermore, additional analyses were performed with adjustment for nutrition-and inflammation-related factors, including body mass index, serum levels of C-reactive protein, hemoglobin, albumin, normalized protein catabolic rate, and % creatinine generation rate. Subsequently, to reduce potential confounding and treatment selection bias, we adjusted the significant difference in baseline covariates with the use of propensity score matching. RESULTS: Data were adjusted using basic factors, with PS as a reference group, and the hazard ratio (HR) was significantly higher in CTA, PMMA, PAN, and EVAL groups. were significantly lower than that for the PS group (P < 0.01). CONCLUSIONS: The use of different membrane types may affect mortality. However, further long-term prospective studies are needed to clarify whether the PES and PMMA membranes can improve prognosis.
